Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:OMER 15 October 2025 - 25 December 2025

Omeros (OMER) Stock Surges After FDA Approval of Yartemlea: Latest News, Analyst Forecasts, and 2026 Outlook

Omeros (OMER) Stock Surges After FDA Approval of Yartemlea: Latest News, Analyst Forecasts, and 2026 Outlook

The FDA approved Omeros’ Yartemlea (narsoplimab-wuug) for adults and children with transplant-associated thrombotic microangiopathy, marking the first approved therapy for this condition. Omeros shares surged to a 52-week high after trading halts and heavy options activity. The company plans a U.S. launch in January 2026. Analysts renewed coverage following the regulatory decision.
25 December 2025
Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros shares jumped 75% to $15.36 in after-hours trading Wednesday after the FDA approved its first commercial product, YARTEMLEA, for a rare post-transplant complication. The stock saw heavy volume and a wide range, with multiple trading halts reported. U.S. markets closed early for Christmas Eve and will reopen Friday. The FDA had previously rejected the drug in 2021.
24 December 2025
··
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Biotech Bombshell: Omeros Stock Skyrockets on $2.1B Novo Nordisk Deal – What’s Next?

Omeros shares soared 150% to $10.42 on Oct. 15 after Novo Nordisk agreed to license its drug zaltenibart (OMS906) for $340 million upfront and up to $2.1 billion in milestones and royalties. Trading volume hit 89.2 million shares, far above average. Omeros reported a Q2 net loss of $25.4 million and $28.7 million in cash as of June 30. Its lead asset narsoplimab remains under FDA and EMA review.
16 October 2025
···
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Omeros shares soared about 146% on Oct. 15, 2025, closing near $10.11 after Novo Nordisk agreed to license its drug zaltenibart for up to $2.1 billion. Omeros will receive $340 million upfront, with the deal expected to close in Q4. The company will now focus on its lead drug narsoplimab, which is under FDA and EMA review. Analyst targets for Omeros stock range from $9 to $36.
15 October 2025
···
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk will pay up to $2.1 billion to license Omeros’s experimental MASP-3 inhibitor zaltenibart for rare blood and kidney disorders. Omeros receives $340 million upfront, with additional milestone and royalty payments possible. Omeros shares jumped about 65% on the news, while Novo’s stock fell 1.5%. The deal is expected to close by Q4 2025.
15 October 2025
···

Stock Market Today

  • JPMorgan Upgrades Capital One Despite 2026 Stock Drop, Sees 10.6% Upside
    April 9, 2026, 9:31 AM EDT. JPMorgan upgraded Capital One Financial to overweight from neutral amid a 20% drop in its 2026 stock price. Analyst Richard Shane cut the price target to $213 but still sees a 10.6% gain from Wednesday's close. The downgrade in price target reflects cautious views on consumer risks, including high energy costs and inflation. Shane cited the completion of Capital One's Discover Financial Services merger as a positive thematic factor. JPMorgan believes Capital One's strong reserves can shield it from worsening macroeconomic conditions, limiting further downside unless new risks materialize. The upgrade signals a buy-the-dip approach despite ongoing economic uncertainty.

Latest article

American Airlines Faces FAA Fine Over Drug-Testing Lapses in New Test for 2026 Turnaround

American Airlines Faces FAA Fine Over Drug-Testing Lapses in New Test for 2026 Turnaround

9 April 2026
The FAA proposed a $255,000 civil penalty against American Airlines, alleging the carrier allowed 12 flight attendants who tested positive for drugs or alcohol to return to safety-sensitive duties before completing required follow-up tests. The alleged violations occurred from May 2019 to December 2023. American has 30 days to respond. The airline said it is reviewing the notice.
Hologic goes private: Blackstone, TPG close buyout and name José Almeida CEO

Hologic goes private: Blackstone, TPG close buyout and name José Almeida CEO

9 April 2026
Blackstone and TPG closed their $17.3 billion acquisition of Hologic on April 7, with José Almeida replacing Steve MacMillan as CEO. Hologic shares were suspended before trading that day and will be removed from the S&P 500 before Thursday’s open. Former shareholders will receive $76 per share in cash plus a contingent value right worth up to $3 more if revenue targets are met.
When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

9 April 2026
Brent crude rebounded 3% Thursday despite a U.S.-Iran ceasefire, with the Strait of Hormuz still nearly shut and only one oil-products tanker passing in 24 hours. U.S. gasoline averaged $4.166 a gallon on April 9, and AAA said prices could drop slowly. North Sea Forties crude hit a record $146.43 a barrel. The U.S. EIA expects Hormuz flows may take months to recover.
CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

9 April 2026
CoreWeave said Meta Platforms committed about $21 billion for AI cloud capacity through December 2032. Shares rose 4.3% to $88.90 in premarket trading after the announcement. The deal follows an $8.5 billion loan facility and a $1.25 billion senior notes offering. CoreWeave reported $5.13 billion in 2025 revenue and ended December with a $66.8 billion backlog.
Go toTop